112 related articles for article (PubMed ID: 3492396)
21. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2).
Jürgenliemk-Schulz IM; Renes IB; Rutgers DH; Everse LA; Bernsen MR; Den Otter W; Battermann JJ
Radiat Oncol Investig; 1997; 5(2):54-61. PubMed ID: 9303058
[TBL] [Abstract][Full Text] [Related]
22. Granulocyte-macrophage colony-stimulating factor-producing tumour vaccines.
Rössner P; Bubeník J; Sobota V; Indrová M; Hájková R; Mendoza L; Jandlová T; Símová J
Folia Biol (Praha); 1999; 45(5):173-7. PubMed ID: 10730885
[TBL] [Abstract][Full Text] [Related]
23. Treatment of transplanted spontaneous rat T-cell leukaemia with local administration of recombinant murine interleukin-2.
Otová B; Panczak A; Símová J; Jandlová T; Bubeník J; Blazek K; Schramlová J; Marinov I
Folia Biol (Praha); 1997; 43(1):25-32. PubMed ID: 9158946
[TBL] [Abstract][Full Text] [Related]
24. Systemic cytokine immunotherapy for experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency.
Dix RD; Giedlin M; Cousins SW
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1411-7. PubMed ID: 9191604
[TBL] [Abstract][Full Text] [Related]
25. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
Donohue JH; Rosenstein M; Chang AE; Lotze MT; Robb RJ; Rosenberg SA
J Immunol; 1984 Apr; 132(4):2123-8. PubMed ID: 6607956
[TBL] [Abstract][Full Text] [Related]
26. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.
Vallera DA; Taylor PA; Aukerman SL; Blazar BR
Cancer Res; 1993 Sep; 53(18):4273-80. PubMed ID: 8364923
[TBL] [Abstract][Full Text] [Related]
27. Local versus systemic interleukin-2: tumor formation by wild-type and B7-1-positive murine melanoma cells.
Barnard AL; Farzaneh F; Gäken J; Darling D
Cancer Gene Ther; 2000 Feb; 7(2):207-14. PubMed ID: 10770628
[TBL] [Abstract][Full Text] [Related]
28. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Aug; 135(2):1488-97. PubMed ID: 3891854
[TBL] [Abstract][Full Text] [Related]
29. Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens.
Baral E; Nagy E; Kangas L; Berczi I
Anticancer Res; 1997; 17(5A):3653-8. PubMed ID: 9413218
[TBL] [Abstract][Full Text] [Related]
30. Tumour inhibitory effects of TCGF/IL-2/-containing preparations.
Bubeník J; Indrová M; Perlmann P; Berzins K; Mach O; Kraml J; Toulcová A
Cancer Immunol Immunother; 1985; 19(1):57-61. PubMed ID: 3872165
[TBL] [Abstract][Full Text] [Related]
31. Radiation therapy enhances the therapeutic effect of immunotherapy on pulmonary metastases in a murine renal adenocarcinoma model.
Chakrabarty A; Hillman GG; Maughan RL; Ali E; Pontes JE; Haas GP
In Vivo; 1994; 8(1):25-31. PubMed ID: 8054507
[TBL] [Abstract][Full Text] [Related]
32. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
Mulé JJ; Shu S; Rosenberg SA
J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
[TBL] [Abstract][Full Text] [Related]
33. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
34. Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin.
Indrová M; Bubeník J; Mikysková R; Vonka V; Smahel M; Zák R; Símová J; Bieblová J; Mendoza L; Jandlová T
Int J Oncol; 2002 Mar; 20(3):643-6. PubMed ID: 11836582
[TBL] [Abstract][Full Text] [Related]
35. IL-2 inhibits the induction of systemic antitumour immunity by IL-4 in the peritumoural treatment of experimental melanoma.
Zaloom Y; Gallagher G
Anticancer Res; 1993; 13(4):1081-5. PubMed ID: 8352529
[TBL] [Abstract][Full Text] [Related]
36. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
McLaughlin JP; Schlom J; Kantor JA; Greiner JW
Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
[TBL] [Abstract][Full Text] [Related]
37. Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.
Forni G; Giovarelli M; Santoni A
J Immunol; 1985 Feb; 134(2):1305-11. PubMed ID: 3871210
[TBL] [Abstract][Full Text] [Related]
38. IL-2 gene-modified tumour vaccines: monitoring of IL-2 levels in serum and peritoneal cavity of vaccinated mice.
Indrová M; Pajtasz-Piasecka E; Jandlová T; Símová J; Bubeník J; Radzikowski C
Folia Biol (Praha); 1999; 45(1):7-11. PubMed ID: 10732712
[TBL] [Abstract][Full Text] [Related]
39. [Potentiation of the antitumoral effect of electrochemotherapy by immunotherapy with allogeneic cells producing interleukin 2].
Mir LM; Roth C; Orlowski S; Belehradek J; Fradelizi D; Paoletti C; Kourilsky P
C R Acad Sci III; 1992; 314(12):539-44. PubMed ID: 1381659
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-2 induction, response and therapy on murine lupus lesions in the MRL/l strain.
Abe C; Koyama A; Nishimura T
Prog Clin Biol Res; 1987; 229():147-56. PubMed ID: 3496609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
